PCM
ACAD icon

Palisade Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Palisade Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-62,928
Closed -$2M – 460
2016
Q3 		$2M Sell
62,928
-9,134
-13% -$310K 0.07% 336
2016
Q2 		$2.34M Sell
72,062
-211,837
-75% -$7.09M 0.08% 310
2016
Q1 		$7.94M Sell
283,899
-211,931
-43% -$4.62M 0.26% 126
2015
Q4 		$17.7M Sell
495,830
-144,722
-23% -$5.1M 0.57% 36
2015
Q3 		$21.2M Sell
640,552
-16,189
-2% -$674K 0.62% 28
2015
Q2 		$27.5M Sell
656,741
-48,560
-7% -$1.88M 0.7% 15
2015
Q1 		$23M Sell
705,301
-296,813
-30% -$10.2M 0.58% 39
2014
Q4 		$31.8M Buy
1,002,114
+29,068
+3% +$824K 0.77% 12
2014
Q3 		$24.1M Sell
973,046
-169,492
-15% -$3.96M 0.61% 26
2014
Q2 		$25.8M Sell
1,142,538
-108,226
-9% -$2.26M 0.62% 23
2014
Q1 		$30.4M Sell
1,250,764
-90,085
-7% -$2.28M 0.75% 14
2013
Q4 		$32.6M Buy
1,340,849
+135,198
+11% +$3.19M 0.85% 9
2013
Q3 		$33.1M Buy
1,205,651
+211,517
+21% +$4.42M 0.9% 6
2013
Q2 		$18M Buy
+994,134
New +$13.7M 0.52% 45

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Palisade Capital Management's ACAD Position: Q4 2016 in Review

Palisade Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 62,928 shares — an estimated $2M sold.

Palisade Capital Management first reported a position in ACAD in Q2 2013 and held it in 14 quarters. The position peaked at $33.1M in Q3 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Palisade Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Palisade Capital Management sold 62,928 Acadia Pharmaceuticals shares in Q4 2016, an estimated $2M.
  • Palisade Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Palisade Capital Management's Acadia Pharmaceuticals position peaked at $33.1M in Q3 2013.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.